- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Prospective, Single centre
- Study aim: To evaluate the efficacy of nirmatrelvir/ritonavir vs. a three-day course of remdesivir in preventing hospitilisation among mainly immunocompromised, vaccinated, high-risk outpatients with COVID-19
- Number of participants enrolled: 521
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- Emergency department
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Nirmatrelvir/Ritonavir
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to